https://doi.org/10.1158/1078-0432.ccr-17-3431
M
Maki Tanioka
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
177
Papers
1.7K
Citations
22
h-index
49
i10-index
Maki Tanioka is an academic researcher from Okayama Shoka University. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Breast Cancer Treatment Studies & Advanced Breast Cancer Therapies. The author has an h-index of 22, co-authored 151 publications.
ORCID: 0000-0002-6558-2246Papers by this author
worksIntegrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
2018 · Clinical Cancer Research · 89 citations
A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy
2013 · British Journal of Cancer · 64 citations
https://doi.org/10.1038/bjc.2013.400
Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy
2010 · British Journal of Cancer · 55 citations
https://doi.org/10.1038/sj.bjc.6605769
Unlocking the transcriptomic potential of formalin-fixed paraffin embedded clinical tissues: comparison of gene expression profiling approaches
2020 · BMC Bioinformatics · 54 citations
https://doi.org/10.1186/s12859-020-3365-5
Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status
2014 · The Breast · 28 citations
https://doi.org/10.1016/j.breast.2014.03.008
Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer
2014 · Breast Cancer Research and Treatment · 21 citations
https://doi.org/10.1007/s10549-014-3121-5
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat